Ahmad Al Maradni, MD
Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1588194112
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,584 of the $5,138 with a category attached, or 89.2%. It is spread thinly across 33 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,821, 6.8 times the $267 reported in 2019.
Across 256 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BETA Bionics, Inc.$679
- Novo Nordisk$472
- Lilly USA, LLC$424
- Senseonics, Incorporated$400
- Corcept Therapeutics$357
- Insulet Corporation$325
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$4008%
- Food & beverage$4,58489%
- Education$952%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BETA Bionics, Inc. | 53 | $679 |
| Novo Nordisk | 26 | $472 |
| Lilly USA, LLC | 21 | $424 |
| Senseonics, Incorporated | 1 | $400 |
| Corcept Therapeutics | 13 | $357 |
| Insulet Corporation | 17 | $325 |
| Xeris Pharmaceuticals, Inc. | 15 | $271 |
| Mannkind Corporation | 11 | $254 |
| Bayer | 12 | $220 |
| Boehringer Ingelheim | 8 | $171 |
| AstraZeneca(2 entities) | 10 | $162 |
| Amgen | 9 | $142 |
| Dexcom, Inc. | 7 | $137 |
| Amneal Pharmaceuticals LLC | 7 | $136 |
| Recordati_rare_diseases_inc. | 7 | $132 |
| Sanofi-aventis U.S. LLC | 5 | $113 |
| Tandem Diabetes Care, Inc. | 4 | $109 |
| Medtronic | 6 | $102 |
| Ascensia Diabetes Care US Inc. | 4 | $82 |
| Radius Health, Inc. | 2 | $49 |
| Sequel Med Tech, LLC | 1 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Averitas Pharma Inc. | 2 | $45 |
| Shire North American Group Inc | 2 | $39 |
| Novartis | 2 | $34 |
| AbbVie | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Biogen | 1 | $26 |
| Cequr Corporation | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Echosens North America, Inc. | 1 | $20 |
| Intra-sana Laboratories | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Eversense$400
How this compares
$5,138 in reported general payments places this provider in the 65th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 211 | $272,981 |
| JardianceEmpagliflozin | 262 | $264,077 |
| TrulicityDulaglutide | 186 | $246,061 |
| FarxigaDapagliflozin Propanediol | 136 | $112,423 |
| TradjentaLinagliptin | 179 | $107,097 |
| MounjaroTirzepatide | 51 | $62,062 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 228 | $26,106 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $25,236 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 45 | $21,373 |
| ProliaDenosumab | 12 | $20,094 |
| JanuviaSitagliptin Phosphate | 18 | $14,507 |
| KerendiaFinerenone | 15 | $13,955 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $13,547 |
| Humalog Kwikpen U-100Insulin Lispro | 50 | $13,086 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $12,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $171 | $371,174441 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $424 | $312,805266 claims |
| Novo NordiskOzempic | $472 | $272,981211 claims |
| AstraZenecaFarxiga | $162 | $112,423136 claims |
| AmgenProlia | $142 | $20,09412 claims |
| BayerKerendia | $220 | $13,95515 claims |
| AbbVieSynthroid | $31 | $4,83662 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $136 | $3,075410 claims |
| Sanofi-aventis U.S. LLCLantus | $113 | $1,49512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Phoenix
- Kevin YuenPhoenix$404K
- Joan BaileyPhoenix$316K
- Anna BoronPhoenix$32K
- Kari EdlingPhoenix$23K
- James DeerPhoenix$13K
- Lory BarazPhoenix$10K
- Sathya JyothinagaramPhoenix$10K
- Philip LevyPhoenix$9K
- Richard ArakakiPhoenix$6K
- Yasmin AkhunjiPhoenix$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.